Fund of the Week: Franklin Biotechnology Discovery Fund (FBDIX)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Fund of the Week: Franklin Biotechnology Discovery Fund (FBDIX)

Franklin Templeton Logo
The Franklin Biotechnology Discovery Fund (FBDIX) is a mutual fund from Franklin Templeton Investments that focuses on companies that are involved in biotechnology and drug discovery. As of October 28, 2014, the fund has $1.6 billion in assets under management (AUM).

As biotechnology stocks continue to rally, we have decided to dig into this fund’s details this week.

Inside the Fund

The Franklin Biotechnology Discovery Fund is currently managed by Franklin Advisors Evan McCulloch (since 1997) and Jerel A. Banks (since 2012).

Year-to-date, the fund is up about 26%, which is in-line with the NASDAQ Biotechnology index. This fund has 100% of its holdings in the healthcare sector. The fund’s holdings range from micro to giant sized. The majority of these holdings are U.S.-based stocks.

Historical Performance

Franklin Biotechnology Discovery Fund’s Largest Holdings

The fund’s top five holdings account for over 33% of its portfolio. Excluding BIIB, all of its top holdings have rallied over the last three months.

The Bottom Line

After the collapse of the biotechnology stocks last spring, the industry has been surging. This fund is a great way to gain exposure to this industry without buying individual stocks.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next

Franklin Templeton Logo

Fund of the Week: Franklin Biotechnology Discovery Fund (FBDIX)

The Franklin Biotechnology Discovery Fund (FBDIX) is a mutual fund from Franklin Templeton Investments that focuses on companies that are involved in biotechnology and drug discovery. As of October 28, 2014, the fund has $1.6 billion in assets under management (AUM).

As biotechnology stocks continue to rally, we have decided to dig into this fund’s details this week.

Inside the Fund

The Franklin Biotechnology Discovery Fund is currently managed by Franklin Advisors Evan McCulloch (since 1997) and Jerel A. Banks (since 2012).

Year-to-date, the fund is up about 26%, which is in-line with the NASDAQ Biotechnology index. This fund has 100% of its holdings in the healthcare sector. The fund’s holdings range from micro to giant sized. The majority of these holdings are U.S.-based stocks.

Historical Performance

Franklin Biotechnology Discovery Fund’s Largest Holdings

The fund’s top five holdings account for over 33% of its portfolio. Excluding BIIB, all of its top holdings have rallied over the last three months.

The Bottom Line

After the collapse of the biotechnology stocks last spring, the industry has been surging. This fund is a great way to gain exposure to this industry without buying individual stocks.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next